Eli Lilly and Company
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
Overall survival is the only viable endpoint for pragmatic trials in oncology, the US FDA and a panel of stakeholders agree, although other novel endpoints could be validated over time. In the meantime, FDA says, sponsors should focus on other aspects of trials that can be streamlined.
Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of , describes the unprecedented growth of the obesity market and what might come next for Novo.
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.
- Other Names / Subsidiaries
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.